Modality
mAb
MOA
HER2
Target
FGFR
Pathway
Incretin
Bladder Ca
Development Pipeline
Preclinical
~Jul 2020
→ ~Oct 2021
Phase 1
~Jan 2022
→ ~Apr 2023
Phase 2
Jul 2023
→ Mar 2031
Phase 2Current
NCT07423984
771 pts·Bladder Ca
2023-07→2031-03·Recruiting
NCT05566375
2,828 pts·Bladder Ca
2023-10→2027-03·Active
3,599 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-03-1611mo awayPh2 Data· Bladder Ca
2031-03-245.0y awayPh2 Data· Bladder Ca
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2
Recruit…
P2
Active
Catalysts
Ph2 Data
2027-03-16 · 11mo away
Bladder Ca
Ph2 Data
2031-03-24 · 5.0y away
Bladder Ca
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07423984 | Phase 2 | Bladder Ca | Recruiting | 771 | MRD |
| NCT05566375 | Phase 2 | Bladder Ca | Active | 2828 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 |